Synairgen completes a successful equity placing to fund the company’s trial for COVID-19 patients
Synairgen plc has raised US$17.6 million to fund the company’s trial for COVID-19 patients.
Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the company uses in vitro and ex vivo models to progress opportunities into clinical development. The biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Synairgen on its oversubscribed equity fundraising to fund the company’s trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients, manufacture of the drug and to strengthen the company’s balance sheet.


Talk to the deal team

Related deals
DierenDokters has been acquired by VetPartners
DierenDokters, a leading group of fourteen veterinary clinics located across the Netherlands, has been acquired by VetPartners, a UK-based group of over 650 veterinary clinics and hospitals located across Europe. By partnering with VetPartners, DierenDokters welcomes a strong new shareholder that will help further enhance DierenDokters’ clinics’ service offering and allow the clinics to continue focusing on providing the best possible animal healthcare services.
Learn moreConnexicon Medical has been acquired by Advanced Medical Solutions PLC
Connexicon Medical Ltd has been sold to Advanced Medical Solutions PLC.
Learn moreTherapy Equipment has been acquired by ESAB Corporation
Owner Venture Managers has sold Therapy Equipment Ltd. to ESAB Corporation.
Learn more